Rockwell Medical Receives Canadian Patent for SFP Formulation for Iron-Delivery in Hemodialysis Patients

Loading...
Loading...
Rockwell Medical
RMTI
, a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, announced today that it has received notice from the Canadian Intellectual Property Office that it has obtained patent issuance for its proprietary GMP formulation for Soluble Ferric Pyrophosphate (SFP), the Company's lead investigational drug that provides iron replacement to hemodialysis patients with CKD.
Posted In: NewsLegal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...